Philipp Harter

32.7k total citations · 7 hit papers
327 papers, 12.3k citations indexed

About

Philipp Harter is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Philipp Harter has authored 327 papers receiving a total of 12.3k indexed citations (citations by other indexed papers that have themselves been cited), including 262 papers in Reproductive Medicine, 120 papers in Oncology and 106 papers in Obstetrics and Gynecology. Recurrent topics in Philipp Harter's work include Ovarian cancer diagnosis and treatment (259 papers), Endometrial and Cervical Cancer Treatments (95 papers) and Intraperitoneal and Appendiceal Malignancies (76 papers). Philipp Harter is often cited by papers focused on Ovarian cancer diagnosis and treatment (259 papers), Endometrial and Cervical Cancer Treatments (95 papers) and Intraperitoneal and Appendiceal Malignancies (76 papers). Philipp Harter collaborates with scholars based in Germany, Italy and Belgium. Philipp Harter's co-authors include Andreas du Bois, Isabelle Ray‐Coquard, Florian Heitz, Ignace Vergote, Alexander Reuß, Jonathan A. Ledermann, Werner Meier, Jacobus Pfisterer, Ursula A. Matulonis and Michael Friedländer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Philipp Harter

304 papers receiving 12.1k citations

Hit Papers

Olaparib Maintenance Therapy in Platinum-Sensitive Relaps... 2009 2026 2014 2020 2012 2009 2014 2016 2022 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
    2012 1.3k citations Jonathan A. Ledermann, Philipp Harter et al. profile →
  2. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
    2009 1.1k citations Andreas du Bois, Alexander Reuß et al. profile →
  3. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
    2014 1.1k citations Jonathan A. Ledermann, Philipp Harter et al. profile →
  4. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
    2016 309 citations Jonathan A. Ledermann, Philipp Harter et al. profile →
  5. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2022 304 citations Ana Oaknin, Philipp Harter et al. profile →
  6. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
    2023 220 citations Ursula A. Matulonis, Domenica Lorusso et al. Journal of Clinical Oncology profile →
  7. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2023 149 citations Antonio González-Martı́n, Philipp Harter et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philipp Harter Germany 50 8.2k 5.3k 3.6k 3.4k 2.3k 327 12.3k
Mark F. Brady United States 42 8.4k 1.0× 3.7k 0.7× 3.7k 1.0× 3.9k 1.1× 2.0k 0.9× 111 12.0k
Éric Pujade-Lauraine France 47 5.6k 0.7× 4.6k 0.9× 2.5k 0.7× 1.6k 0.5× 2.1k 0.9× 319 10.0k
Helen Huang United States 30 4.8k 0.6× 2.9k 0.5× 2.7k 0.8× 2.6k 0.8× 1.3k 0.6× 68 8.1k
Claes G. Tropé Norway 47 4.4k 0.5× 2.4k 0.4× 2.3k 0.6× 2.1k 0.6× 2.7k 1.2× 216 8.6k
Antonio González-Martı́n Spain 40 3.5k 0.4× 4.1k 0.8× 1.1k 0.3× 1.7k 0.5× 1.4k 0.6× 307 7.5k
Brian N. Bundy United States 50 10.0k 1.2× 4.4k 0.8× 9.2k 2.6× 13.0k 3.8× 1.9k 0.8× 111 22.3k
John A. Blessing United States 61 6.2k 0.8× 3.0k 0.6× 4.0k 1.1× 7.7k 2.3× 1.8k 0.8× 261 13.1k
Alexandra Léary France 38 2.6k 0.3× 3.5k 0.6× 879 0.2× 2.4k 0.7× 2.0k 0.9× 280 7.5k
Amreen Husain United States 32 2.5k 0.3× 4.7k 0.9× 1.1k 0.3× 1.7k 0.5× 1.5k 0.6× 74 8.2k
Mansoor Raza Mirza Denmark 34 3.6k 0.4× 2.6k 0.5× 952 0.3× 2.4k 0.7× 1.3k 0.6× 228 6.4k

Countries citing papers authored by Philipp Harter

Since Specialization
Citations

This map shows the geographic impact of Philipp Harter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philipp Harter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philipp Harter more than expected).

Fields of papers citing papers by Philipp Harter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philipp Harter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philipp Harter. The network helps show where Philipp Harter may publish in the future.

Co-authorship network of co-authors of Philipp Harter

This figure shows the co-authorship network connecting the top 25 collaborators of Philipp Harter. A scholar is included among the top collaborators of Philipp Harter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philipp Harter. Philipp Harter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marmé, Frederik, Philipp Harter, Andrés Redondo, et al.. (2024). Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.. Journal of Clinical Oncology. 42(17_suppl). LBA5501–LBA5501. 9 indexed citations
2.
Hattesohl, Akira, Julia Teply‐Szymanski, Florian Heitz, et al.. (2024). Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer—Development of Recommendations for Optimal Assay Performance. Modern Pathology. 37(4). 100445–100445. 5 indexed citations
3.
Fendler, Wolfgang P., Kim M. Pabst, Rainer Hamacher, et al.. (2023). 68Ga-FAPI-46 PET for cancer imaging: A prospective single-arm clinical trial.. Journal of Clinical Oncology. 41(16_suppl). 3064–3064. 1 indexed citations
4.
Reichardt, Peter, Philipp Harter, Stefan Kommoss, et al.. (2023). Uterine sarcoma patients who underwent morcellation: Who are they? Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA- NOGGO RU1).. Journal of Clinical Oncology. 41(16_suppl). e17632–e17632.
5.
Tsibulak, Irina, Stephanie Schneider, Alexander Traut, et al.. (2023). #644 Surgical management of FIGO stage IV epithelial ovarian cancer versus FIGO stage IIIC: the real-world experience from KEM. A37–A38. 1 indexed citations
6.
7.
8.
Mirza, Mansoor Raza, David M. O’Malley, Philipp Harter, et al.. (2022). 2022-RA-439-ESGO Up-next (ENGOT-Ov71-NSGO-CTU/GOG-3049): a study of upitifamab rilsodotin (UpRi), a napi2b-directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer. International Journal of Gynecological Cancer. 32. A234–A234. 1 indexed citations
9.
Fotopoulou, Christina, Jalid Sehouli, Ignace Vergote, et al.. (2022). 2022-RA-276-ESGO Value of surgical cytoreduction for subsequent ovarian cancer relapse in patients previously treated with chemotherapy alone at 1st-relapse: a subanalysis of the DESKTOP III/ENGOT-ov20 trial. International Journal of Gynecological Cancer. 32. A227–A228. 1 indexed citations
10.
Ataseven, Beyhan, et al.. (2022). 2022-RA-778-ESGO Rare gynecological cancers in a gynecologic cancer center: 11-year experience of KEM. International Journal of Gynecological Cancer. 32. A189–A190. 1 indexed citations
11.
Ataseven, Beyhan, Chiara Cassani, Marco D’Indinosante, et al.. (2022). Ovarian cancer onset across different BRCA mutation types: a view to a more tailored approach for BRCA mutated patients. International Journal of Gynecological Cancer. 33(2). 257–262. 3 indexed citations
12.
Ángeles, Martina Aida, Nicolò Bizzarri, Natalia R. Gómez‐Hidalgo, et al.. (2022). Interviews from the European Society of Gynaecological Oncology 2021 Congress: an IJGC-ENYGO Fellows compilation. International Journal of Gynecological Cancer. 32(4). 468–473. 1 indexed citations
13.
Friedländer, Michael, Sarah J. Lord, Rebecca Asher, et al.. (2021). Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. European Journal of Cancer. 154. 190–200. 9 indexed citations
14.
Bois, Andreas du, Philipp Harter, Christina Fotopoulou, et al.. (2019). TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7). International Journal of Gynecological Cancer. 29(8). 1327–1331. 114 indexed citations
15.
Pfisterer, Jacobus, Jürgen Hedderich, Éric Pujade-Lauraine, et al.. (2019). Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years. Gynecologic Oncology. 153(3). 616–624. 6 indexed citations
16.
Prader, Sonia, Andreas du Bois, Florian Heitz, et al.. (2018). Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer. Gynecologic Oncology. 152(1). 76–81. 27 indexed citations
17.
Harter, Philipp, Pier Francesco Alesina, Dietmar Lorenz, et al.. (2014). Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. Gynecologic Oncology. 132(3). 537–541. 33 indexed citations
18.
Heitz, Florian, Philipp Harter, Jana Barinoff, et al.. (2012). Bevacizumab in the Treatment of Ovarian Cancer. Advances in Therapy. 29(9). 723–735. 32 indexed citations
19.
Schüler, Martin, Ahmad Awada, Philipp Harter, et al.. (2012). A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment. 134(3). 1149–1159. 71 indexed citations
20.
Engels, Knut, Shirley K. Knauer, Sibylle Loibl, et al.. (2008). NO Signaling Confers Cytoprotectivity through the Survivin Network in Ovarian Carcinomas. Cancer Research. 68(13). 5159–5166. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark F. Brady Breakdown of academic impact, for papers by Éric Pujade-Lauraine Breakdown of academic impact, for papers by Helen Huang Breakdown of academic impact, for papers by Claes G. Tropé Breakdown of academic impact, for papers by Antonio González-Martı́n Breakdown of academic impact, for papers by Brian N. Bundy Breakdown of academic impact, for papers by John A. Blessing Breakdown of academic impact, for papers by Alexandra Léary Breakdown of academic impact, for papers by Amreen Husain Breakdown of academic impact, for papers by Mansoor Raza Mirza
Rankless by CCL
2026